Overview

A Study to Develop Additional Safety and Clinical Experience With NATRECOR hBNP (Nesiritide) in the Treatment of Patients With Worsening Congestive Heart Failure Who Require Inpatient Intravenous Therapy With Medications That Influence the Tone and

Status:
Completed
Trial end date:
1997-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this safety study is to evaluate NATRECOR® hBNP (a recombinant form of the natural human peptide normally secreted by the heart in response to heart failure), in subjects with worsening congestive heart failure for whom inpatient intravenous therapy with medications that influence the tone and caliber of blood vessels is deemed appropriate.
Phase:
Phase 3
Details
Lead Sponsor:
Scios, Inc.
Treatments:
Natriuretic Peptide, Brain